Press release
Immuno-oncology Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025
According to the World Health Organization (WHO), cancer was responsible for 8.8 million deaths in 2015. Owing to benefits associated with these therapies, the leading players are actively investing in research and development into this treatment category through various collaborations and individual research studies. For instance, EMD Serono is involved in research and development of immune-oncology drugs and has a few drugs in pipeline such as M7824 (investigational) bifunctional immunotherapy. In 2015, Merck & Co., a leading drug manufacturer and MD Anderson Cancer Center entered into a strategic clinical research collaboration for formers drug Keytruda (Pembrolizumab). Celsee Diagnostics and IncellDx announced an immuno-oncology research agreement in 2017. Bristol-Myers Squibb is developing immuno-oncology approaches for treatment of colorectal cancer, lung cancer, melanoma, liver cancer, lymphoma, multiple myeloma, and others. Amgen, Inc. is actively involved in immune-oncology research and the company launched an immunotherapy collaboration with Kite Pharma to develop and commercialize chimeric antigen receptor (CAR) T cells in 2015.
However, high cost of immuno-oncology therapies, which is unaffordable to low and middle class population is restraining growth of the market. For instance Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg.
Ask for detailed Sample of the Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1271
*The Sample consists of Table of Content, Research framework of the actual report & research methodology adopted for it
Cancer treatment has become more refined with improved treatment success rate due to improved therapeutic outcomes. This has been possible due to deepened understanding of the disease pathophysiology, functioning of the tumor cells, and effective ways to tackle with the same. Immuno-oncology therapies exhibit lesser side effects as compared to conventional cancer therapies such as chemotherapy, radiation therapy, and others. Immuno-oncology therapy directly target the immune system of the body and does not harm healthy cells in the process, whereas, conventional therapies such as targeted therapy, chemotherapy, and radiation therapy affect cancerous as well as healthy cells extensively. Novel immune therapies can restore the ability of the immune system to identify and eliminate cancer cells, which is generally suppressed during course of cancer progression. Manufactures are developing immuno-oncology based therapies, which are tailored to attack or block particular targets. For instance, Iplimumab, a, human monoclonal antibody, which blocks cytotoxic T-lymphocyte-associated antigen-4 is available. Furthermore, agents focusing on specific immune regulatory checkpoints programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1) such as Nivolumab, Atezolimumab, and Pembrolizumab are being used for cell lung cancer. Monoclonal antibodies have been further developed into conjugated monoclonal antibodies, which are combined with other agents such as radiolabeled antibodies and chemo labeled antibodies. Cancer vaccines have also been developed such as Sipuleucel-T, Gardasil, and Cervarix. These vaccines either work as preventive vaccines or therapeutic vaccines. Adoptive cell transfer therapies is a new therapy emerging in the immuno-oncology such as CAR-T Cell Therapy under, which Kymriah and Yescarta are available.
The global immuno-oncology drugs market was valued at US$ 43,084.5 million in 2016 and is expected to witness a robust CAGR of 14.9% over the forecast period (2017 – 2025).
Immuno-oncology involves use of patients’ immune system to fight against cancer. Immuno-oncology uses novel immunotherapies that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immuno-oncology does not affect the functioning of healthy cells as opposed to conventional therapies such as chemotherapy and radiation therapy. Long term response can be generated with the help of these therapies as they provide long-lasting memory to the immune system. Immune system adapts to the cancer over time and provides long term response to the cancer. Immuno-Oncology therapy work against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine based immunotherapy, cancer vaccines, and other therapies. Depending on the functioning of these therapies they are further classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies, and bispecific monoclonal antibodies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.
To know more about the Immuno-oncology Drugs Market, click the link below: https://www.coherentmarketinsights.com/market-insight/immuno-oncology-drugs-market-1271
“Catch us at 3rd International Conference on Separation + Drying Technologies for Milk & Whey at Cologne, March 19 and 20, 2018”
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immuno-oncology Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025 here
News-ID: 981012 • Views: …
More Releases from Market Research Report: CMI
Pompe Disease Therapeutic Market- Global Industry Analysis, Size, Share, Growth, …
Manufacturers are focusing on finding new solutions by expanding their pipeline to cater the demand for pompe disease therapeutics market. For instance, in September, 2017, Avrobio Inc. expanded their products pipeline with gene therapy to treat pompe disease by utilizing a proprietary lysosomal targeting sequence to deliver high levels of enzyme to lysosomes. Furthermore, in October 2017, Amicus Therapeutics received orphan drug designation to ATB200/AT2221 from the U.S. FDA for…
Companion Animal Drugs Market - Global Industry Analysis, Size, Share, Growth, T …
According to the report by Association for Pet Obesity Prevention (APOP), in 2016, there is a continuous increase in pet obesity, affecting around 54% of dogs and 59% of cats in U.S. Pet obesity is a major problem in U.S., which increases the pain and suffering and also affects the life expectancy of companion animal or pet. According to APOP, factors causing pet obesity include negligence of pet owners and…
Blood Clotting Factors Market - Global Industry Analysis, Size, Share, Growth, T …
Haemophilia is a rare disorder affecting very small fraction of population across the globe. Pharmaceutical companies invest less amount on development of such drugs due to low return on investment. However, FDA has recognised this fact and has formulated favourable policy to motivate companies to invest in this area. Orphan Drug Act that applies to company operating in this area provides three special incentives i.e. 7 years exclusivity period, tax…
Chagas Disease Treatment Market - Insights, Trends, Outlook, and Opportunity Ana …
In 2017, Food and Drug Administration (FDA) approved benznidazole for children suffering from Chagas, in the age group of 2 to 12 years. This is the first approved safe and effective therapeutic for Chagas in the U.S. FDA granted benznidazole priority review and orphan product designation, as it is a rare disease and there have been no approved drugs for its treatment in the U.S. This approval is expected to…
More Releases for Drugs
Generic Drugs Market Application Anti-Infective Drugs, Anti-Arthritis Drugs, Ant …
Generic drugs are the medications that are developed to be similar to a medicine that is already commercially available in the market with a brand name. The generic drug is similar to the medicine available in terms of dosage, safety and strength, mode of administration, quality and intended use. Due to the similarities, generic drugs are capable of treating various diseases. Generic drugs are most cost effective than the branded…
Cytotoxic Drugs Market Growing Demand for Antimetabolite Drugs
According to Precision Business Insights (PBI), the latest report, the cytotoxic drugs market is expected to be valued at USD 15,927.2 million in 2022 and is poised to grow at a significant CAGR of 2.2% over 2022-2028. The primary drivers of the expansion of the global cytotoxic drugs market include the increasing prevalence of cancer diseases, the increasing use and approval of cytotoxic drugs, and the increasing consumption of alcohol…
Global Antithrombotic Drugs Market | Global Antithrombotic Drugs Industry | Glob …
Antithrombotic drugs are special drugs that help to prevent the formation of thrombus or clot. These drugs are used to reduce the formation of blood clots by reducing the capability of body to form a blood clot. Antithrombotic drugs act by preventing the production of vitamin K in the liver. Anticoagulant, antiplatelet, and thrombolytic agents are different types of antithrombotic agents that act by different clotting processes. Arterial & venous…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
Hepatitis Drugs Market by Therapeutics, Diagnostics, Patient, Drugs Policy
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market.
Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market
Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest…
Epilepsy Drugs Market by Country, Drugs, Company & Forecast
For More Information:
https://renub-research.blogspot.com/2019/04/the-factors-that-are-driving-global.html
Epilepsy is a chronic disease in which patient’s brain activities become abnormal due to seizures. Seizure is an unexpected rush of electrical activity in the brain. Seizure is categorized by two types - generalized seizures and focal or partial seizures. Generalized seizures affect the whole brain whereas focal or partial seizures affect just one part of the brain. Global epilepsy drugs market is expected to cross US$…
